Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)
Clinical trial NCT00717925 · COMPLETED
Trial details
- NCT number
- NCT00717925
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2007-03-01
- Primary completion
- 2008-07-01
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.